Vir Biotechnology, Inc. $VIR Shares Sold by Deutsche Bank AG

Deutsche Bank AG lowered its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 3.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 208,290 shares of the company’s stock after selling 8,444 shares during the quarter. Deutsche Bank AG owned 0.15% of Vir Biotechnology worth $1,350,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VIR. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vir Biotechnology in the fourth quarter valued at $42,000. GAMMA Investing LLC lifted its holdings in Vir Biotechnology by 524.3% in the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after acquiring an additional 5,972 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Vir Biotechnology by 26.2% in the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock valued at $68,000 after acquiring an additional 2,171 shares during the period. Syon Capital LLC acquired a new stake in Vir Biotechnology in the fourth quarter valued at $77,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Vir Biotechnology in the first quarter valued at $78,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on VIR shares. Raymond James Financial started coverage on Vir Biotechnology in a report on Friday, July 11th. They issued an “outperform” rating for the company. Needham & Company LLC restated a “buy” rating and issued a $14.00 price target on shares of Vir Biotechnology in a research report on Thursday, May 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $30.25.

Insider Transactions at Vir Biotechnology

In related news, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total transaction of $37,174.12. Following the completion of the sale, the executive vice president owned 108,204 shares in the company, valued at approximately $591,875.88. This trade represents a 5.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $4.99, for a total value of $109,780.00. Following the sale, the director owned 1,276,391 shares of the company’s stock, valued at approximately $6,369,191.09. This represents a 1.69% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 57,582 shares of company stock valued at $294,930. 16.00% of the stock is currently owned by company insiders.

Vir Biotechnology Stock Up 4.6%

Shares of VIR stock opened at $4.58 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The stock has a market cap of $636.25 million, a P/E ratio of -1.15 and a beta of 1.18. The business has a fifty day simple moving average of $5.13 and a 200-day simple moving average of $6.04.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The firm had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The company’s quarterly revenue was down 60.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.02) EPS. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).